31 January 2019
Visiongain has launched a new pharma report Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029 : North America, Europe, India, Rest of the World (RoW).
This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017. It analyses the leading companies operating in the generic drug market and discusses forces that shape companies’ strategic directions. There have been a number of consolidation activities, mergers, acquisitions and divestitures occurring amongst the leading players in the generic drugs market over the last few years. This level of corporate activities has led to the creation of a market which is steep in growth opportunities for companies that are able to align their strategies to growth.
The lead analyst of the report commented "Related to the move towards biosimilars and the decreasing distance between originator and generic companies is the rise of the complex generics sector. As generics competition steadily increases in all markets, there are strong incentives for companies with sufficiently advanced technologies to move beyond simple generics into more complex, higher-margin products.
With differentiation likely to increase in importance as the generics market becomes more competitive, novel delivery systems and reformulations (for example, extended-release versions of original products) will also increase in significance for generics companies. Competitive strength in this field will require investment in ongoing R&D, further contributing to the closure of the gap between original and generic manufacturers."
Leading companies featured in the report include Abbott, Aurobindo, EMS, Endo, Fresenius, Kabi, Mylan, Novartis (Sandoz), Pfizer, Sun Pharmaceuticals, Teva.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
06 April 2021
Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.
01 April 2021
Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.